STING1 and breast cancer: The article delves into the intricate interplay between the activation status of the cGAS-STING pathway and the tumor immune microenvironment across distinct breast cancer subtypes, elucidating how these interactions may lead to divergent clinical outcomes—either beneficial or detrimental.